Document Detail


Superoxide dismutase decreases reperfusion arrhythmias and preserves myocardial function during thrombolysis with tissue plasminogen activator.
MedLine Citation:
PMID:  1696653     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Release of superoxide radicals during the early phase of coronary reperfusion may result in degradation of endothelium-derived relaxing factor (EDRF), extension of myocardial injury, precipitation of arrhythmias, and stimulation of platelet aggregation. These factors may relate to the occurrence of ventricular fibrillation during reperfusion and coronary reocclusion following initial thrombolysis. This study was designed to examine the effects of concomitant administration of superoxide radical scavenger superoxide dismutase (SOD) with tissue plasminogen activator (tPA) compared to tPA alone (without SOD) in acute coronary thrombosis in anesthetized dogs. Dogs with a stable electrically induced coronary thrombus were randomly given intravenously tPA (0.75 mg/kg) alone or SOD bolus (2 mg/kg) followed by SOD (4 mg/kg) + tPA (0.75 mg/kg) over 20 min. tPA alone restored coronary blood flow in six of nine dogs (reperfusion rate of 67%) with time to reflow of 18.5 +/- 6.7 (mean +/- SD) min. Coronary reocclusion occurred spontaneously in four of six dogs with initial reperfusion (reocclusion rate of 67%). In contrast, SOD + tPA restored coronary blood flow in 9 of 12 dogs (reperfusion rate of 75%, not significant vs. tPA alone) with time to reflow of 11.3 +/- 4.8 min and coronary reocclusion occurred in only 3 of 9 dogs with reperfusion (reocclusion rate of 33%, not significant vs. tPA alone). Reperfusion arrhythmias were more frequent in dogs who received tPA alone compared to those who received SOD in addition to tPA (mean Holter-monitored PVC count of 730 vs. 12 beats/h, p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)
Authors:
J L Mehta; W W Nichols; T G Saldeen; V K Chandna; F A Nicolini; D L Lawson; M F ter Riet
Related Documents :
3335053 - Effects of calcium channel blocker on responses of blood flow, function, arrhythmias, a...
10807653 - Caspase inhibition and limitation of myocardial infarct size: protection against lethal...
2112623 - Incidence of arrhythmia with central venous catheter insertion and exchange.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  16     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  1990 Jul 
Date Detail:
Created Date:  1990-09-18     Completed Date:  1990-09-18     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  112-20     Citation Subset:  IM    
Affiliation:
Department of Medicine, University of Florida College of Medicine, Gainesville.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acetylcholine / pharmacology
Animals
Arrhythmias, Cardiac / etiology,  physiopathology,  prevention & control*
Coronary Disease / drug therapy*
Coronary Thrombosis / complications,  drug therapy*,  physiopathology
Coronary Vessels / drug effects
Dogs
Female
Heart / drug effects*
Hemodynamics / drug effects
Myocardial Reperfusion
Platelet Aggregation / drug effects
Recombinant Proteins / therapeutic use
Superoxide Dismutase / therapeutic use*
Thrombolytic Therapy*
Tissue Plasminogen Activator / pharmacology,  therapeutic use*
Chemical
Reg. No./Substance:
0/Recombinant Proteins; 51-84-3/Acetylcholine; EC 1.15.1.1/Superoxide Dismutase; EC 3.4.21.68/Tissue Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pharmacokinetics of recombinant human superoxide dismutase.
Next Document:  Ceranapril (SQ 29,852), an orally active inhibitor of angiotensin converting enzyme (ACE).